Karabulut Senem, Keskin Serkan, Ekenel Meltem, Basaran Mert, Agaoglu Fulya, Ozger Harzem, Bavbek Sevil
Departments of Medical Oncology, Istanbul University, 34390 Istanbul, Turkey.
Radiation Oncology, Institute of Oncology, Istanbul University, 34390 Istanbul, Turkey.
Mol Clin Oncol. 2013 Nov;1(6):1061-1064. doi: 10.3892/mco.2013.185. Epub 2013 Sep 17.
Desmoid tumors (DTs) are benign tumors that exhibit fibroblastic proliferation, which arises from fascial or musculoaponeurotic structures. The aim of this study was to investigate the characteristics and outcomes of patients with resectable DTs. A total of 21 patients were included and their clinicopathological characteristics were retrospectively analyzed. The 21 patients (16 females and 5 males) were identified through reviewing the patient charts at our institute. The tumor was located in the lower extremities in 7 cases, in the upper extremities in 4 cases, in the abdominal region in 9 cases and in the neck region in 1 case. Patients who had been initially treated by surgical excision were included in the study. Of these 21 patients, a positive surgical margin (SM) was reported in 11 patients, 7 of whom received postoperative radiotherapy (RT). Ten patients had a negative SM and 6 received RT. A total of 5 patients (46%) in the positive SM group and 4 (40%) in the negative SM group had documented disease relapse (P>0.05). The median relapse-free survival (RFS) was 20.5 months for the patients treated by surgery alone and 50 months for those treated with surgery followed by adjuvant RT (P>0.05). Age, gender, SM and adjuvant RT were not identified as predictors of recurrence. No predictive factors appeared to indicate local DT recurrence following surgery.
硬纤维瘤（DTs）是一种表现为成纤维细胞增殖的良性肿瘤，起源于筋膜或肌-腱膜结构。本研究的目的是调查可切除性硬纤维瘤患者的特征和预后。共纳入21例患者，并对其临床病理特征进行回顾性分析。通过查阅我院病历确定了这21例患者（16例女性和5例男性）。肿瘤位于下肢7例，上肢4例，腹部9例，颈部1例。纳入最初接受手术切除治疗的患者。在这21例患者中，11例报告手术切缘（SM）阳性，其中7例接受了术后放疗（RT）。10例患者手术切缘阴性，6例接受了放疗。手术切缘阳性组共有5例患者（46%）记录到疾病复发，手术切缘阴性组有4例患者（40%）复发（P>0.05）。单纯手术治疗患者的无复发生存期（RFS）中位数为20.5个月，手术联合辅助放疗患者的无复发生存期为50个月（P>0.05）。年龄、性别、手术切缘和辅助放疗未被确定为复发的预测因素。似乎没有预测因素可提示术后硬纤维瘤局部复发。
